Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis
Authors:
- Ihsan FadilahIFIhsan Fadilah
- Robert J. CommonsRCRobert J. Commons
- Nguyen Hoang ChauNCNguyen Hoang Chau
- Gavin C. K. W. KohGKGavin C. K. W. Koh
- Marcus Vg LacerdaMLMarcus Vg Lacerda
- Alejandro Llanos-CuentasALAlejandro Llanos-Cuentas
- Erni J. NelwanENErni J. Nelwan
- Francois NostenFNFrancois Nosten
- Ayodhia Pitaloka PasaribuAPAyodhia Pitaloka Pasaribu
Open Access
- 27 September 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (9) , e1004411
Abstract
Background: The 8-aminoquinolines, primaquine and tafenoquine, are the only available drugs for the radical cure of Plasmodium vivax hypnozoites. Previous evidence suggests that there is dose-dependent 8-aminoquinoline induced methaemoglobinaemia and that higher methaemoglobin concentrations are associated with a lower risk of P. vivax recurrence. We undertook a systematic review and individual patient data meta-analysis to examine the utility of methaemoglobin as a population-level surrogate endpoint for 8-aminoquinoline antihypnozoite activity to prevent P. vivax recurrence. Methods and findings: We conducted a systematic search of Medline, Embase, Web of Science, and the Cochrane Library, from 1 January 2000 to 29 September 2022, inclusive, of prospective clinical efficacy studies of acute, uncomplicated P. vivax malaria mono-infections treated with radical curative doses of primaquine. The day 7 methaemoglobin concentration was the primary surrogate outcome of interest. The primary clinical outcome was the time to first P. vivax recurrence between day 7 and day 120 after enrolment. We used multivariable Cox proportional-hazards regression with site random-effects to characterise the time to first recurrence as a function of the day 7 methaemoglobin percentage (log base 2 transformed), adjusted for the partner schizonticidal drug, the primaquine regimen duration as a proxy for the total primaquine dose (mg base/kg), the daily primaquine dose (mg/kg), and other factors. The systematic review protocol was registered with PROSPERO (CRD42023345956). We identified 219 P. vivax efficacy studies, of which 8 provided relevant individual-level data from patients treated with primaquine; all were randomised, parallel arm clinical trials assessed as having low or moderate risk of bias. In the primary analysis data set, there were 1,747 patients with normal glucose-6-phosphate dehydrogenase (G6PD) activity enrolled from 24 study sites across 8 different countries (Indonesia, Brazil, Vietnam, Thailand, Peru, Colombia, Ethiopia, and India). We observed an increasing dose-response relationship between the daily weight-adjusted primaquine dose and day 7 methaemoglobin level. For a given primaquine dose regimen, an observed doubling in day 7 methaemoglobin percentage was associated with an estimated 30% reduction in the risk of P. vivax recurrence (adjusted hazard ratio = 0.70; 95% confidence interval [CI] [0.57, 0.86]; p = 0.0005). These pooled estimates were largely consistent across the study sites. Using day 7 methaemoglobin as a surrogate endpoint for recurrence would reduce required sample sizes by approximately 40%. Study limitations include the inability to distinguish between recrudescence, reinfection, and relapse in P. vivax recurrences. Conclusions: For a given primaquine regimen, higher methaemoglobin on day 7 was associated with a reduced risk of P. vivax recurrence. Under our proposed causal model, this justifies the use of methaemoglobin as a population-level surrogate endpoint for primaquine antihypnozoite activity in patients with P. vivax malaria who have normal G6PD activity.Keywords
Funding Information
- Oxford Nuffield Department of Medicine Tropical Network Fund
- National Health and Medical Research Council (2008501)
- National Health and Medical Research Council (1194701)
- Wellcome Trust (220211)
- Wellcome Trust (089179)
- National Council for Scientific and Technological Development
- CSL Centenary Fellowships
- Wellcome Trust (223253/Z/21/Z)
- Wellcome Trust (093956/Z/10/C)
- Medicines for Malaria Venture
- Medicines for Malaria Venture
- GlaxoSmithKline
- Wellcome Trust
- Sanaria
This publication has 43 references indexed in Scilit:
- An increase in urinary primaquine and a reduction in urinary primaquine-5,6-orthoquinone in the Thai population with CYP2D6 reduced enzyme functionHeliyon, 2024
- A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialseClinicalMedicine, 2023
- Two‐stage or not two‐stage? That is the question for IPD meta‐analysis projectsResearch Synthesis Methods, 2023
- Understanding pulse oximetry in hematology patients: Hemoglobinopathies, racial differences, and beyondAmerican Journal of Hematology, 2022
- Individual participant data meta‐analysis to examine interactions between treatment effect and participant‐level covariates: Statistical recommendations for conduct and planningStatistics in Medicine, 2020
- Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling studyThe Lancet, 2019
- Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for LatentPlasmodium vivaxMalariaJAMA Network Open, 2018
- The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trialsInternational Journal for Parasitology: Drugs and Drug Resistance, 2017
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant DataJAMA, 2015
- Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection studyThe Lancet, 2014